{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:46:58Z","timestamp":1778615218828,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jaad.2013.10.043","type":"journal-article","created":{"date-parts":[[2013,12,24]],"date-time":"2013-12-24T20:15:15Z","timestamp":1387916115000},"page":"555-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Specific targeting of interleukin-23p19 as effective treatment for psoriasis"],"prefix":"10.1016","volume":"70","author":[{"given":"Adriane A.","family":"Levin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice B.","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2013.10.043_bib1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s11926-007-0075-1","article-title":"Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines","volume":"9","author":"Fitch","year":"2007","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.jaad.2013.10.043_bib2","doi-asserted-by":"crossref","DOI":"10.3410\/B2-40","article-title":"The role of IL-23 in the immunopathogenesis of psoriasis","volume":"2","author":"Di Meglio","year":"2010","journal-title":"F1000 Biol Rep"},{"key":"10.1016\/j.jaad.2013.10.043_bib3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1346-8138.2011.01458.x","article-title":"Critical role of the interleukin-23\/T-helper 17 cell axis in the pathogenesis of psoriasis","volume":"39","author":"Nakajima","year":"2012","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2013.10.043_bib5","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/archdermatol.2010.168","article-title":"Increased IL-23 expression in palmoplantar psoriasis and hyperkeratotic hand dermatitis","volume":"146","author":"Lillis","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2567.2011.03522.x","article-title":"Interleukin-23: as a drug target for autoimmune inflammatory diseases","volume":"135","author":"Tang","year":"2012","journal-title":"Immunology"},{"key":"10.1016\/j.jaad.2013.10.043_bib7","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/jid.2009.59","article-title":"The IL-23\/Th17 axis in the immunopathogenesis of psoriasis","volume":"129","author":"Di Cesare","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/jir.2010.0083","article-title":"Interleukin-23-induced interleukin-23 receptor subunit expression is mediated by\u00a0the Janus kinase\/signal transducer and activation of transcription pathway in human CD4 T cells","volume":"31","author":"Che Mat","year":"2011","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jaad.2013.10.043_bib9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3899\/jrheum.120234","article-title":"Th17 and interleukin 23 in the pathogenesis of psoriatic arthritis and spondyloarthritis","volume":"89","author":"Cauli","year":"2012","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.jaad.2013.10.043_bib10","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2013.10.043_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2165\/11595940-000000000-00000","article-title":"Briakinumab for the treatment of plaque psoriasis","volume":"26","author":"Traczewski","year":"2012","journal-title":"BioDrugs"},{"key":"10.1016\/j.jaad.2013.10.043_bib12","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.4049\/jimmunol.176.3.1908","article-title":"In\u00a0vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin","volume":"176","author":"Piskin","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2013.10.043_bib13","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.4049\/jimmunol.1000148","article-title":"Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model","volume":"186","author":"Nakajima","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2013.10.043_bib14","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/jid.2010.432","article-title":"IL-23-mediated epidermal hyperplasia is dependent on IL-6","volume":"131","author":"Lindroos","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib15","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1172\/JCI37378","article-title":"CCR6 is required for IL-23-induced psoriasis-like inflammation in mice","volume":"119","author":"Hedrick","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2013.10.043_bib16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0923-1811(02)00072-5","article-title":"Interleukin-12 p40 gene (IL12B) 3'-untranslated region polymorphism is associated with susceptibility to atopic dermatitis and psoriasis vulgaris","volume":"30","author":"Tsunemi","year":"2002","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2013.10.043_bib17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/511051","article-title":"A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes","volume":"80","author":"Cargill","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.jaad.2013.10.043_bib18","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00439-007-0397-0","article-title":"Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis","volume":"122","author":"Capon","year":"2007","journal-title":"Human genetics"},{"key":"10.1016\/j.jaad.2013.10.043_bib19","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/jid.2009.319","article-title":"Molecular dissection of psoriasis: integrating genetics and biology","volume":"130","author":"Elder","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00403-009-0986-y","article-title":"Genetic evidence for involvement of the IL23 pathway in Thai psoriatics","volume":"302","author":"Nair","year":"2010","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2013.10.043_bib21","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1038\/jid.2013.170","article-title":"The IL23R A\/Gln381 allele promotes IL-23 unresponsiveness in human memory T-helper 17 cells and\u00a0impairs Th17 responses in psoriasis patients","volume":"133","author":"Di Meglio","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib22","doi-asserted-by":"crossref","first-page":"7563","DOI":"10.4049\/jimmunol.166.12.7563","article-title":"Ubiquitous transgenic expression of the\u00a0IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death","volume":"166","author":"Wiekowski","year":"2001","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2013.10.043_bib23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1084\/jem.20041257","article-title":"IL-23 drives a pathogenic T cell population that induces autoimmune inflammation","volume":"201","author":"Langrish","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.jaad.2013.10.043_bib24","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature01355","article-title":"Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain","volume":"421","author":"Cua","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2013.10.043_bib25","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1172\/JCI25308","article-title":"Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis","volume":"116","author":"Chen","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2013.10.043_bib26","doi-asserted-by":"crossref","first-page":"7104","DOI":"10.4049\/jimmunol.169.12.7104","article-title":"IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination","volume":"169","author":"Gran","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2013.10.043_bib27","doi-asserted-by":"crossref","first-page":"R93","DOI":"10.1186\/ar3817","article-title":"Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features","volume":"14","author":"Celis","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2013.10.043_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/kel306","article-title":"Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system","volume":"46","author":"Szodoray","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2013.10.043_bib29","doi-asserted-by":"crossref","first-page":"R96","DOI":"10.1186\/ar2297","article-title":"IL-23 induces human osteoclastogenesis via\u00a0IL-17 in\u00a0vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats","volume":"9","author":"Yago","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2013.10.043_bib30","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4\u2013CD8\u2013 entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2013.10.043_bib31","first-page":"597","article-title":"IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation","volume":"118","author":"Ma","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2013.10.043_bib32","doi-asserted-by":"crossref","first-page":"539683","DOI":"10.1155\/2012\/539683","article-title":"The Th17\/IL-23 axis and natural immunity in psoriatic arthritis","volume":"2012","author":"Maeda","year":"2012","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib33","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.4049\/jimmunol.1001538","article-title":"Cutting edge: a critical functional role for IL-23 in psoriasis","volume":"185","author":"Tonel","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2013.10.043_bib34","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.smim.2007.10.012","article-title":"The link between IL-23 and Th17 cell-mediated immune pathologies","volume":"19","author":"McGeachy","year":"2007","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaad.2013.10.043_bib35","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3390\/ijms11030789","article-title":"Interleukin 12 a key immunoregulatory cytokine in infection applications","volume":"11","author":"Hamza","year":"2010","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2013.10.043_bib36","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2007.07.016","article-title":"Interleukin-12, interleukin-23, and psoriasis: current prospects","volume":"57","author":"Torti","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib37","doi-asserted-by":"crossref","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","article-title":"Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes","volume":"86","author":"Grossman","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jaad.2013.10.043_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2012.10899.x","article-title":"Elevated serum levels of interleukin 21 are associated with disease severity in patients with psoriasis","volume":"167","author":"He","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib39","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jdermsci.2010.08.016","article-title":"IL-21 in the pathogenesis and treatment of skin diseases","volume":"60","author":"Costanzo","year":"2010","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.jaad.2013.10.043_bib40","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.4161\/cc.8.22.9964","article-title":"Pathogenic role of interleukin-21 in psoriasis","volume":"8","author":"Caruso","year":"2009","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jaad.2013.10.043_bib41","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature07021","article-title":"IL-21 and TGF-beta are required for differentiation of human T(H)17 cells","volume":"454","author":"Yang","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2013.10.043_bib42","first-page":"660","article-title":"A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2\/IL21","volume":"164","author":"Warren","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib43","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","article-title":"Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial","volume":"144","author":"Kimball","year":"2008","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib44","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa062382","article-title":"A human interleukin-12\/23 monoclonal antibody for the treatment of psoriasis","volume":"356","author":"Krueger","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.10.043_bib45","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2012.10901.x","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years","volume":"166","author":"Kimball","year":"2012","journal-title":"Br J Dermatol"},{"issue":"Suppl","key":"10.1016\/j.jaad.2013.10.043_bib46","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3310\/hta13Suppl3-10","article-title":"Ustekinumab for the treatment of moderate to severe psoriasis","volume":"13","author":"Gospodarevskaya","year":"2009","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jaad.2013.10.043_bib47","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/09546634.2012.672710","article-title":"Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis","volume":"24","author":"Au","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2013.10.043_bib48","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.10.043_bib49","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomized, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2013.10.043_bib50","unstructured":"Ustekinumab approved for psoriatic arthritis in US, Europe. Medscape, Sept 23, 2013."},{"key":"10.1016\/j.jaad.2013.10.043_bib51","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2013.10.043_bib52","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1365-2133.2011.10418.x","article-title":"Efficacy and safety of briakinumab vs etanercept and placebo in patients with moderate to severe chronic plaque psoriasis","volume":"165","author":"Gottlieb","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib53","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A phase III, randomized, controlled trial\u00a0of\u00a0the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2013.10.043_bib54","unstructured":"Papp K, Thaci D, Riedl E, Reich K, Langley R, Krueger J, et\u00a0al. Dose-dependent improvement in chronic plaque psoriasis following treatment with anti-ILp19 humanized monoclonal antibody (MK-222). Waterloo, Ontario, Canada: Probidity Medical Research. 2013."},{"key":"10.1016\/j.jaad.2013.10.043_bib55","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s13555-012-0016-4","article-title":"Emerging therapies for the treatment of psoriasis","volume":"2","author":"Patel","year":"2012","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2013.10.043_bib56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1146\/annurev.immunol.16.1.495","article-title":"The interleukin-12\/interleukin-12-receptor system: role in normal and pathologic immune responses","volume":"16","author":"Gately","year":"1998","journal-title":"Ann Rev Immunol"},{"key":"10.1016\/j.jaad.2013.10.043_bib57","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0161-5890(02)00017-2","article-title":"Inherited disorders of IL-12- and\u00a0IFNgamma-mediated immunity: a molecular genetics update","volume":"38","author":"Doffinger","year":"2002","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jaad.2013.10.043_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10875-006-7830-3","article-title":"Presentation of interleukin-12\/-23 receptor beta1 deficiency with various clinical symptoms of Salmonella infections","volume":"26","author":"Sanal","year":"2006","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.jaad.2013.10.043_bib59","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1086\/425021","article-title":"Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans","volume":"190","author":"MacLennan","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jaad.2013.10.043_bib60","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1128\/IAI.00621-06","article-title":"Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection","volume":"74","author":"Chackerian","year":"2006","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2013.10.043_bib61","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1128\/IAI.73.9.5782-5788.2005","article-title":"Pulmonary interleukin-23 gene delivery increases local T-cell immunity and controls growth of Mycobacterium tuberculosis in the lungs","volume":"73","author":"Happel","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2013.10.043_bib62","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4049\/jimmunol.175.2.788","article-title":"IL-23 compensates for the absence\u00a0of IL-12p70 and is essential for the IL-17 response during tuberculosis but is dispensable for protection and\u00a0antigen-specific IFN-gamma responses if IL-12p70 is available","volume":"175","author":"Khader","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2013.10.043_bib63","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1128\/IAI.01329-06","article-title":"Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection","volume":"75","author":"Rudner","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.jaad.2013.10.043_bib64","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.4049\/jimmunol.176.2.1098","article-title":"IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12","volume":"176","author":"Kleinschek","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2013.10.043_bib65","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.4049\/jimmunol.173.3.1887","article-title":"IL-23 provides a limited mechanism of resistance to acute Toxoplasmosis in the absence of IL-12","volume":"173","author":"Lieberman","year":"2004","journal-title":"J Immunol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213011602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962213011602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:31:08Z","timestamp":1759271468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962213011602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0190962213011602"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2013.10.043","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Specific targeting of interleukin-23p19 as effective treatment for psoriasis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2013.10.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}